Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Protalix Says Gaucher Drug Met Goals in Trial

By Pharmaceutical Processing | October 15, 2009

NEW YORK (AP) — Protalix BioTherapeutics Inc. said Thursday a late-stage study of its Gaucher disease drug met its primary goals. The company said patients taking Uplyso had significantly smaller spleen volume, which is a symptom of Gaucher disease, a rare enzyme disorder that can cause liver and neurological problems. Patients also had greater hemoglobin levels and decreased liver size. The study tested two doses of intravenous Uplyso on 31 patients around the world. Protalix said patients who received the larger dose had a significant reduction in blood platelet counts. Patients who were given the smaller dose had lower blood platelet levels, but the improvement was not statistically significant. Patients in the nine-month trial received a dose of Uplyso every two weeks. The doses were either 30 milligrams per kilogram of the patient’s body weight, or 60 milligrams per kilogram. Protalix said both patient groups had significantly lower spleen volumes after six months of treatment, and there were no serious side effects in the trial. Two of the 31 patients experienced hypersensitivity, and two developed antibodies to the drug, it said. The Israeli company plans to complete a filing for Food and Drug Administration approval before the end of 2009. It had been developing Uplyso under the name prGCD.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE